King A Paden, Gellineau Hendryck A, Ahn Jung-Eun, MacMillan Samantha N, Wilson Justin J
Department of Chemistry and Chemical Biology, Cornell University , Ithaca, New York 14853, United States.
Inorg Chem. 2017 Jun 5;56(11):6609-6623. doi: 10.1021/acs.inorgchem.7b00710. Epub 2017 May 16.
Nine bis(thiosemicarbazone) (BTSC) cobalt(III) complexes of the general formula [Co(BTSC)(L)]NO were synthesized, where BTSC = diacetyl bis(thiosemicarbazone) (ATS), pyruvaldehyde bis(thiosemicarbazone) (PTS), or glyoxal bis(thiosemicarbazone) (GTS) and L = ammonia, imidazole (Im), or benzylamine (BnA). These compounds were characterized by multinuclear NMR spectroscopy, mass spectrometry, cyclic voltammetry, and X-ray crystallography. Their stability in phosphate-buffered saline was investigated and found to be highly dependent on the nature of the axial ligand, L. These studies revealed that complex stability is primarily dictated by the axial ligand following the sequence NH > Im > BnA. The cellular uptake and cytotoxicity in cancer cells were also determined. Both the cellular uptake and cytotoxicity were significantly affected by the nature of the equatorial BTSC. Complexes of ATS were taken up much more effectively than those of PTS and GTS. The cytotoxicity of the complexes was correlated to that of the free ligand. Cell uptake and cytotoxicity were also determined under hypoxic conditions. Only minor differences in the hypoxia activity and uptake were observed. Treatment of the cancer cells with the copper-depleting agent tetrathiomolybdate decreased the cytotoxic potency of the complexes, indicating that they may operate via a copper-dependent mechanism. These results provide a structure-activity relationship for this class of compounds, which may be applied for the rational design of new cobalt(III) anticancer agents.
合成了九个通式为[Co(BTSC)(L)]NO的双(硫代半卡巴腙)(BTSC)钴(III)配合物,其中BTSC = 二乙酰双(硫代半卡巴腙)(ATS)、丙酮醛双(硫代半卡巴腙)(PTS)或乙二醛双(硫代半卡巴腙)(GTS),L = 氨、咪唑(Im)或苄胺(BnA)。这些化合物通过多核核磁共振光谱、质谱、循环伏安法和X射线晶体学进行了表征。研究了它们在磷酸盐缓冲盐水中的稳定性,发现其高度依赖于轴向配体L的性质。这些研究表明,配合物的稳定性主要由轴向配体决定,顺序为NH > Im > BnA。还测定了它们在癌细胞中的细胞摄取和细胞毒性。细胞摄取和细胞毒性均受到赤道面BTSC性质的显著影响。ATS的配合物比PTS和GTS的配合物摄取效率高得多。配合物的细胞毒性与游离配体的细胞毒性相关。还在缺氧条件下测定了细胞摄取和细胞毒性。仅观察到缺氧活性和摄取方面的微小差异。用铜螯合剂四硫代钼酸盐处理癌细胞降低了配合物的细胞毒性效力,表明它们可能通过铜依赖性机制起作用。这些结果为这类化合物提供了构效关系,可用于合理设计新型钴(III)抗癌剂。